TY - JOUR T1 - In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. JF - Invest New Drugs Y1 - 2012 A1 - Zauli, Giorgio A1 - Corallini, Federica A1 - Zorzet, Sonia A1 - Grill, Vittorio A1 - Marzari, Roberto A1 - Secchiero, Paola KW - Animals KW - Humans KW - Immunotherapy KW - Injections, Intraperitoneal KW - Lymphoma, B-Cell KW - Mice KW - Mice, SCID KW - Receptors, TNF-Related Apoptosis-Inducing Ligand KW - Single-Chain Antibodies KW - Time Factors KW - Xenograft Model Antitumor Assays AB -

A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10 mg/kg) were able to significantly increase the median survival time of lymphoma-bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.

VL - 30 IS - 1 U1 - http://www.ncbi.nlm.nih.gov/pubmed/20714918?dopt=Abstract ER -